within Pharmacolibrary.Drugs.ATC.R;

model R03DA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Etamiphylline is a xanthine derivative with bronchodilator properties, structurally related to theophylline, and was previously used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is no longer widely used or approved in most countries, having been largely replaced by other agents.</p><h4>Pharmacokinetics</h4><p>No primary pharmacokinetic publication with explicit model parameters found. Values listed below are estimates based on related xanthine derivatives and sparse pharmacokinetic summaries for adults.</p><h4>References</h4><ol><li><p>Torres, A, et al., &amp; Bruseghini, L (1980). [Serum levels and urinary and fecal excretion of ethamicylin HCI (solucylin). Oral and intravenous administration (author&#x27;s transl)]. <i>Archivos de farmacologia y toxicologia</i> 6(3) 237–246. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7305455/\">https://pubmed.ncbi.nlm.nih.gov/7305455</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DA06;
